(two extradural and one acute subdural) with postoperative hemispheric brain swelling. Compressed basal cisterns were appreciated in all of the cases and seven patients underwent surgery for mass lesion. Table 1 provides a summary of the clinical data, CT findings, and outcomes of the 11 patients.
Treatment and Record Keeping
Intracranial pressure and mean arterial blood pressure (MABP) measurements were obtained from the nurse's bedside "end-hour" notes according to Traumatic Coma Data Bank methodology, 6 and rectal temperature was recorded throughout the treatment. The ICP was monitored with a Richmond subdural screw in nine cases and with a subdural catheter in five cases of patients operated on for mass lesions. Three of the patients were monitored by both methods: a subdural Richmond screw initially and a subdural catheter after surgery. Standard therapy was initiated to maintain ICP under 20 mm Hg and CPP above 70 to 80 mm Hg. This therapy consisted of hyperventilation reaching a mean PaCO 2 of 24.8 Ϯ 7.1 mm Hg; mannitol at a dosage of 0.25 g/kg each time ICP surpassed 20 mm Hg; and barbiturates (thiopental) administered as a bolus or infusion only when ICP could not be maintained under 20 mm Hg with hyperventilation and mannitol. Thiopental infusion (2-3 g/day) was only given when the original bolus of 0.2 to 0.3 g was effective. If the 0.2-to 0.3-g bolus was slightly effective, it was repeated intermittently. Indomethacin treatment was only begun after the previous therapy proved ineffective. At this time the patients had a mean ICP of 34.4 Ϯ 13.1 mm Hg. Throughout the treatment we assessed the effects of 1) an indomethacin bolus (50 mg, 20 minutes) on ICP and CPP; 2) an indomethacin infusion (21.5 Ϯ 11.4 mg/hour, 30 Ϯ 9 hours) on ICP, CPP, rectal temperature, and additional standard therapy regimens (matching values before and during infusion in a similar time interval); and 3) discontinuation of indomethacin on ICP, CPP, and rectal temperature evaluated 24 hours after interruption of treatment.
Statistical Analysis
All values are given as the mean Ϯ standard deviation. We used the t-test for paired data; a calculated difference of probability less than 0.05 was considered to be statistically significant. Table 2 lists the effects of the indomethacin bolus and infusion on ICP and CPP in each patient. * Abbreviations: GCS = Glasgow Coma Scale; CT = computerized tomography; CHT = closed head trauma; EH = extradural hematoma; HS = hemispheric swelling; UC = unilateral contusion; BS = brain swelling; SH = subdural hematoma; SSAH = spontaneous subarachnoid hemorrhage; IH = intracranial hematoma; GS = gunshot wound; DAI = diffuse axonal injury. (Fig. 1A) (Fig. 1B) . With indomethacin infusion ICP decreased from 29.5 Ϯ 9.9 mm Hg to 23.1 Ϯ 9.7 mm Hg (p Ͻ 0.02) (Fig. 1C) and CPP increased from 63.3 Ϯ 9.8 mm Hg to 65.6 Ϯ 8.5 mm Hg (Fig. 1D) . These results were not significant (p = 0.4) and no changes in rectal temperature were recorded. Standard therapy was maintained before and throughout the trial of indomethacin. Hyperventilation changed from a mean PaCO 2 of 24.8 mm Hg prior to indomethacin infusion to 25.9 mm Hg during the infusion (p = 0.6). Administration of mannitol varied from 114 g before indomethacin infusion to 85 g during the infusion (p = 0.1). Thiopental was given at a mean dose of 0.74 g before the indomethacin infusion was begun; during indomethacin infusion the dose of thiopental was raised to 1.05 g, a difference not considered significant. Two patients (Cases 7 and 9) received a 2-g dose per day of thiopental infusion both before and during indomethacin. The other patients received thiopental as an intermittent bolus before and during indomethacin infusion. It should be noted that in three cases mannitol reestablished its effects during indomethacin infusion. One example (Case 1) is shown in Fig.  3 . Adverse effects of indomethacin were not observed.
Results
After administration of indomethacin was discontinued, ICP increased from 21.3 to 31.8 mm Hg, a change that was significant (p Ͻ 0.003). Cerebral perfusion pressure decreased from 71.4 to 64.4 mm Hg (Fig. 2) ; however, this change was not statistically significant (p Ͻ 0.08). Rectal temperature increased significantly from 37.2Њ to 37.9ЊC (p Ͻ 0.007).
Discussion
On the basis of our data and a review of the literature, we believe that the action of indomethacin is mediated through the following three mechanisms.
First, like Jensen and colleagues, 3 we found the indomethacin bolus to exert a very effective action on lowering ICP and improving CPP. However, we used in- domethacin infusion over a longer period than these authors and found that its effect did not fade away rapidly in time. This fact, together with the risks of rebound that were observed as a consequence of indomethacin discontinuation, led us to believe that the vasoactive effect of indomethacin is paramount and that this effectiveness continues for a longer period of time than previously considered. 3 Second, it has been asserted that standard therapy for increased ICP is only effective if some degree of autoregulation is maintained or if, at least, CO 2 reactivity is preserved. 12 Although the standard therapy observed before and during indomethacin infusion did not appear to effect significant changes, the fact that in three cases mannitol reestablished its action on ICP and CPP during indomethacin infusion was consistent with the view that indomethacin could have a beneficial effect on cerebral autoregulation. 9 Third, it is also probable that the beneficial effects of indomethacin infusion could be due to nonvascular actions on baseline ICP in pathological conditions such as ischemic and vasogenic edema. 1, 4, 14 Decreased production of cerebrospinal fluid following endothelin potentiation has been recently demonstrated. 13 Although we did not record cerebral temperature, we did find that the effect of indomethacin could not be attributed to reduction in rectal temperature.
In this study we found indomethacin to be a safe drug with good hemodynamic tolerance and no sedative sideeffects. Although we did not measure cerebral blood flow and cerebral metabolic rate for oxygen, we did not observe areas of ischemia or infarction on follow-up CT scans. We believe that indomethacin should not only be considered a last option for treatment but that it can be considered as one of the frontline therapeutic agents for raised ICP and impaired CPP. We must caution, however, against a sudden interruption of indomethacin infusion because of a real risk of ICP rebound.
